<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885855</url>
  </required_header>
  <id_info>
    <org_study_id>MOH-8v12-SOF/RDV-01-HCV</org_study_id>
    <nct_id>NCT04885855</nct_id>
  </id_info>
  <brief_title>8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C</brief_title>
  <official_title>Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muhammad Radzi Abu Hassan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Sultanah Bahiyah</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is open-label, randomized, multicentre study to compare the efficacy and safety of the&#xD;
      8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C&#xD;
      patients.&#xD;
&#xD;
      All the recruited subjects will receive the treatment accordingly and be followed up for 24&#xD;
      weeks following the completion of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks upon completion of treatment</time_frame>
    <description>Sustained Virological Response (SVR) at week-12 post treatment, as evidenced by Hepatitis C Viral (HCV) ribonucleic acid (RNA) level less than the lower limit of quantification of 15 IU/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>8-week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 MG</intervention_name>
    <description>Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)</description>
    <arm_group_label>12-week</arm_group_label>
    <arm_group_label>8-week</arm_group_label>
    <other_name>Grateziano</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir 200mg</intervention_name>
    <description>Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)</description>
    <arm_group_label>12-week</arm_group_label>
    <arm_group_label>8-week</arm_group_label>
    <other_name>PPI-668</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has evidence of chronic HCV infection, defined as:&#xD;
&#xD;
             a. Positive anti-HCV antibody or detectable HCV RNA or HCV genotype and HCV viral load&#xD;
             ≥104 IU/mL within 6 months prior to the time of blood collection for screening.&#xD;
&#xD;
          2. Willing and able to provide written informed consent.&#xD;
&#xD;
          3. Men and women age ≥ 18 years and &lt; 70 years.&#xD;
&#xD;
          4. Body Mass Index (BMI) of 18 to 35 kg/m2.&#xD;
&#xD;
          5. Intention to comply with the dosing instructions for study drug administration and&#xD;
             able to complete the study schedule of assessments.&#xD;
&#xD;
          6. Women with a negative pregnancy test at screening and baseline assessment.&#xD;
&#xD;
          7. Women of childbearing potential who accept effective contraception from 2 weeks prior&#xD;
             to day 1 of study to 1 month after treatment (double contraceptive method including at&#xD;
             least one barrier method). A woman is of non-childbearing potential if she (a) reached&#xD;
             natural menopause determined retrospectively after 12 months of amenorrhea without any&#xD;
             other obvious medical cause or (b) had procedures like bilateral tubal ligation or&#xD;
             hysterectomy or bilateral oophorectomy.&#xD;
&#xD;
          8. Subjects who are compliant in opioid substitution maintenance program may be included&#xD;
             as long as there is no concern about study medications adherence and interaction or&#xD;
             compliance to study schedules.&#xD;
&#xD;
          9. HIV/HCV co-infected patients receiving cART fulfilling the below criteria are eligible&#xD;
             for the study:&#xD;
&#xD;
               1. Antiretroviral therapy has been initiated at least 6 months prior to screening&#xD;
                  (to avoid the possibility of Immune reconstitution inflammatory syndrome - IRIS)&#xD;
&#xD;
               2. Patient has been on the same protocol-approved ARV regimen for ≥ 8 weeks prior to&#xD;
                  screening and is expected to continue the current ARV regimen through the end of&#xD;
                  study.&#xD;
&#xD;
               3. HIV ARVs: agents allowed in this study should be administered per the prescribing&#xD;
                  information in the package insert&#xD;
&#xD;
               4. Screening HIV RNA &lt;50 copies/mL.&#xD;
&#xD;
               5. Screening CD4 cell count ≥100 cells/uL&#xD;
&#xD;
         10. HIV/HCV co-infected patients not receiving cART: Screening CD4 cell count must be ≥&#xD;
             500 cells/uL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has evidence of liver cirrhosis in which, liver cirrhosis is determined by;&#xD;
&#xD;
               1. APRI score of ≥ 1.5,&#xD;
&#xD;
               2. In case where APRI score is &gt;1.0 but &lt;1.5,&#xD;
&#xD;
                    -  Perform fibroscan* (where TE ≥12.5 kPa indicates liver cirrhosis) or&#xD;
&#xD;
                    -  Calculate FIB-4 index (where ≥3.25 indicates liver cirrhosis) *Depending on&#xD;
                       availability at facility&#xD;
&#xD;
               3. Current/past history of decompensation including ascites, variceal bleeding,&#xD;
                  bacterial peritonitis, or hepatic encephalopathy.&#xD;
&#xD;
          2. Additional laboratory exclusion criteria:&#xD;
&#xD;
               1. Direct bilirubin &gt;3x ULN&#xD;
&#xD;
               2. AST, ALT &gt;10x ULN&#xD;
&#xD;
               3. Low neutrophil count (≤599 cells/mm3), haemoglobin (&lt;9.0 g/dL), platelets&#xD;
                  (&lt;150000 cells/mm3).&#xD;
&#xD;
          3. Patients with serum creatinine &gt;1.5 ULN or end-stage renal disease.2&#xD;
&#xD;
          4. Hepatitis B co-infection (HBsAg positive).&#xD;
&#xD;
          5. Pregnancy, as documented by positive pregnancy tests at screening and baseline&#xD;
             assessment.&#xD;
&#xD;
          6. Breastfeeding.&#xD;
&#xD;
          7. Subjects currently receiving or unable to stop the use for at least 1 week prior to&#xD;
             receiving the first dose of study drug any medications or herbal supplements known to&#xD;
             be potent inhibitors or moderate inducers of cytochrome P450 (CYP) 3A4 and potent&#xD;
             inducers of P-glycoprotein. This includes subjects who are on amiodarone or other&#xD;
             contraindicated drugs. Refer to www.hep_druginteractions.org, the investigator manual&#xD;
             and the investigator's brochure for detailed information.&#xD;
&#xD;
          8. Participation in other clinical trials within 3 months.&#xD;
&#xD;
          9. Any clinically significant findings or unstable condition during the screening,&#xD;
             medical history or physical examination that, in the investigator's opinion, would&#xD;
             compromise participation in this study. This could include patients with poorly&#xD;
             controlled hypertension, asthma, diabetes, or other life-threatening conditions.&#xD;
&#xD;
         10. Current or history of use within the preceding 6 months of immunosuppressive or&#xD;
             immune-modulating agents. Corticosteroid used to treat any medical condition are&#xD;
             allowed if systemic for not more than 2 weeks or if topical.&#xD;
&#xD;
         11. History of solid organ or bone marrow transplantation.&#xD;
&#xD;
         12. Any prior DAA use or NS5A inhibitors therapy.&#xD;
&#xD;
         13. Patients with significant cardiovascular conditions including myocardial infarction&#xD;
             within the previous 6 months or heart failure NYHA class III or IV; history of Torsade&#xD;
             de pointes&#xD;
&#xD;
         14. HIV/HCV co-infected patients who are yet to receive stable antiretroviral therapy or&#xD;
             for whom ART treatment initiation maybe scheduled during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Radzi Abu Hassan, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sultanah Bahiyah, Ministry of Health Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Radzi Abu Hassan, FRCP</last_name>
    <phone>+60194151565</phone>
    <email>drradzi91@yahoo.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah</name>
      <address>
        <city>Alor Star</city>
        <state>Kedah</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Radzi Abu Hassan, FRCP</last_name>
      <email>drradzi91@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sultanah Bahiyah</investigator_affiliation>
    <investigator_full_name>Muhammad Radzi Abu Hassan</investigator_full_name>
    <investigator_title>Consultant Gastroenterologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

